ABBV - AbbVie Inc.
| Previous Close | 93.01 |
| Open | 93.41 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 92.02 - 93.80 |
| 52 Week Range | 64.26 - 125.86 |
| Volume | 4,754,776 |
| Avg. Volume | 7,660,876 |
| Market Cap | 146.928B |
| Beta | 1.64 |
| PE Ratio (TTM) | 28.06 |
| EPS (TTM) | 3.30 |
| Earnings Date | Apr 26, 2018 |
| Forward Dividend & Yield | 3.84 (4.18%) |
| Ex-Dividend Date | 2018-04-12 |
| 1y Target Est | 121.38 |
- Simply Wall St.•2 days ago
AbbVie And Other Great Pharma And Biotech Income Stocks
Pharmaceutical and biotech stocks are rarely seen as effective dividend stocks. Although drugs are also relatively non-cyclical these stocks are often impacted by ever-changing regulatory environment and the strength ofRead More...
InvestorPlace•3 days agoMylan NV Could Be Closer to a Breakout Than Most Traders Realize
If it seems like Mylan NV (NASDAQ:MYL) has gotten far more media attention of late than it usually does — almost all of it bullish — you’re not crazy. The recent investor-day event helped the company toot its own horn to be sure, still, MYL stock has been strangely stuck in neutral in recent days. It’s a curious situation that defies the news Mylan has been dishing out that’s been turning some heads.
Market Realist•3 days agoGilead Sciences Expects Decline in Earnings in Fiscal 2018
Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.
- Moody's•3 days ago
Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising
The global pharmaceutical industry will see annual earnings growth of 1%-2% over the next 12 to 18 months, supporting a stable outlook on the sector, Moody's Investors Service says in its just-released report. The rating agency's stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas. Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range.
- Zacks•4 days ago
Roche Hemophilia Drug Gets Breakthrough Therapy Designation
The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.
Market Realist•4 days agoGilead Sciences May Witness Significant Drop in Revenues in 2018
Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...
Market Realist•4 days agoWhat Analysts Recommend for Gilead Sciences in April 2018
In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.
Market Realist•4 days agoAnalysts’ Recommendations for AbbVie in April 2018
In April 2018, the FDA notified AbbVie (ABBV) and Neurocrine Biosciences that it would need more time to review liver function test data provided by AbbVie with its new drug application for Elagolix for the management of endometriosis-associated pain, extending its Prescription Drug User Fee Act goal date by three months to 3Q18. In 4Q17, the FDA granted Elagolix priority review. In clinical trials, Elagolix was evaluated for safety and efficacy in ~1,700 women with moderate-to-severe endometriosis-related pain.
- PR Newswire•4 days ago
AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference
NORTH CHICAGO, Ill. , April 18, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Deutsche Bank's 43 rd Annual Health Care Conference ...
Market Realist•4 days agoAbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane
In 4Q17, AbbVie’s (ABBV) Duodopa generated revenue of $100 million, marking ~28% growth YoY (year-over-year) and 6% growth quarter-over-quarter. In US and international markets, Duodopa saw revenue of $17 million and $77 million, respectively, reflecting ~55.2% and ~23% growth YoY.
- Zacks•4 days ago
The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox
The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox
- Zacks•5 days ago
Top Analyst Reports for AbbVie, Berkshire & PepsiCo
Top Analyst Reports for AbbVie, Berkshire & PepsiCo
- Investopedia•5 days ago
7 Stock Picks With Giant Upside: Goldman
Green Pastures: DISH, AbbVie, Hasbro and other stocks are poised to flourish
- Zacks•5 days ago
5 Drug Stocks Poised to Surpass on Earnings This Quarter
The outlook for the upcoming first-quarter results looks bright.
- Market Realist•5 days ago
Novartis’s 1Q18: Analysts Expect Revenue Growth
Analysts expect Novartis’s (NVS) revenue to rise ~8.8% to $12.6 billion in 1Q18 following growth in operating revenues across all three of its segments during the quarter.
- Market Realist•5 days ago
Updates on AbbVie’s AndroGel, Lupron, and Kaletra
In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter. In fiscal 2017, AndroGel generated revenue of $577 million, marking a ~14.5% decline YoY.
- Market Realist•5 days ago
Risankizumab Could Be AbbVie’s Long-Term Growth Driver
In December 2017, AbbVie (ABBV) announced positive top-line results for its pivotal Phase 3 IMMhance trial to evaluate the safety and efficacy of risankizumab 150 mg1 for the treatment of individuals with moderate-to-severe plaque psoriasis.
Market Realist•5 days agoAbbVie’s Imbruvica in 4Q17 and Fiscal 2017
AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.
- Market Realist•6 days ago
How AbbVie’s Humira Performed in 4Q17 and 2017
AbbVie’s (ABBV) Humira generated revenue of $4.9 billion in 4Q17 and $4.3 billion in 4Q16, reflecting ~14% growth YoY (year-over-year) and ~4% growth quarter-over-quarter. In 4Q17, in US and international markets, Humira reported revenue of $3.3 billion and $1.6 billion, respectively, marking ~15.1% and ~11.7% growth YoY.
- Market Realist•6 days ago
Upadacitinib Could Drive AbbVie’s Long-Term Growth
In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis. The trial met its primary endpoint of improved ACR201 scores and clinical remission.
- GlobeNewswire•6 days ago
Consolidated Research: 2018 Summary Expectations for Amazon, Rayonier, The Boeing, Sanchez Energy, AbbVie, and American Airlines Group — Fundamental Analysis, Key Performance Indications
NEW YORK, April 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Market Realist•6 days ago
Johnson & Johnson’s Revenue Estimates for 1Q18
As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17. Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment. The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor.
- Zacks•9 days ago
Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.
- Market Realist•9 days ago
Exploring Voyager Therapeutics’ Research Pipeline
Voyager Therapeutics’ (VYGR) research pipeline consists of six programs targeting different neurological indications, including advanced Parkinson’s disease, amyotrophic lateral sclerosis (or ALS), Huntington’s disease, and Alzheimer’s disease. Voyager Therapeutics’ most advanced clinical candidate is VY-AADC for the treatment of advanced Parkinson’s disease.
- Motley Fool•9 days ago
Better Buy: AbbVie Inc. vs. Eli Lilly
How the giant drugmakers compare when it comes to growth, dividends, and valuation.
